Absci Corporation (ABSI) News
Track canonical SquawkNews coverage tagged to ABSI, Absci Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 31 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Absci Corporation (ABSI) Plans Phase 2 ABS-201 Endometriosis Trial for Mid-2027
Absci detailed a planned global, randomized Phase 2 trial of ABS-201 in endometriosis, targeting ~150 patients and a mid-2027 initiation, subject to regulatory clearance and protocol finalization.Material DetailsContext
NEWS | Sep 24, 2026, 12:03 PM UTC
L
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP)Anticipated initiation of Phase 2 trial in mid-2027VANCOUVER,
NEWS | Sep 24, 2026, 12:03 PM UTC
L
ABSI - Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI -Designed Antibody ABS-201™ for Endometriosis
ABSI - Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI -Designed Antibody ABS-201™ for Endometriosis
NEWS | Sep 24, 2026, 12:00 PM UTC
L
Absci Price Target Maintained With a $11.00/Share by Needham
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 11:09 AM UTC
L
Needham reiterates Buy rating on Absci, $11 price target
Needham reiterated their Buy rating on Absci's stock with a price target of $11.00.The price target implies an upside of 2.7% from the Sep 22 close of $10.71.Key takeaways from the analyst noteStrong Product Candidate: A
EQUITY | Sep 23, 2026, 10:59 AM UTC
L
Absci Initiated at Outperform by LifeSci Capital
Ratings actions from Benzinga
EQUITY | Sep 09, 2026, 09:05 PM UTC
L
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
AUSTIN, Texas, Sept. 3, 2026 // -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug dis
EQUITY | Sep 03, 2026, 12:55 PM UTC
L
Absci to participate in upcoming investor conferences
Absci Corporation said it will participate in upcoming investor conferences, as detailed in a company announcement.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
ABSI - Absci to Participate in Upcoming Investor Conferences
ABSI - Absci to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 12:01 PM UTC
L
Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
EQUITY | Aug 28, 2026, 10:00 AM UTC
L
ABSI Trades Lower On Q2 Results
ABSI shares are trading lower after reporting worse-than-expected Q2 financial results
EARNINGS | Aug 11, 2026, 08:53 PM UTC
L
Absci Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $318.000K Miss $1.169M Estimate
Absci (NASDAQ: ABSI ) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 12.5 percent increase over losses of $(0.24) per share from the same per
EARNINGS | Aug 11, 2026, 08:08 PM UTC
L
ABSI - Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
ABSI - Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
EQUITY | Aug 11, 2026, 08:05 PM UTC
L
As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models
As AI Models Become Commodities, a Bio-Native AI Compan
EQUITY | Jul 06, 2026, 12:55 PM UTC
L
The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
The Quantum Sector Hits an Inflection Point: Federal Mo
EQUITY | Jul 06, 2026, 12:45 PM UTC
L
Truist Securities Maintains Buy on Absci, Raises Price Target to $17
Truist Securities analyst Srikripa Devarakonda maintains Absci (NASDAQ: ABSI ) with a Buy and raises the price target from $11 to $17.
EQUITY | Jul 02, 2026, 12:32 PM UTC
H
Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AI
While corporate America is becoming more selective about using artificial intelligence as a rationale for acquisitions, Anthropic is making its biggest bet yet that AI will reshape scientific research. The AI startup on
MNA | Jul 01, 2026, 11:50 AM UTC
H
Analysts Cut/Boost Targets
Top Wall Street analysts change outlook on several stocks, including Micron, Nike, and PepsiCo, with price target cuts and boosts
EQUITY | Jun 25, 2026, 01:06 PM UTC
M
ABSI: HC Wainwright Raises PT
HC Wainwright & Co. maintains Buy on Absci and raises price target to $16
EQUITY | Jun 25, 2026, 12:07 PM UTC
M
ABSI: Needham Reiterates Buy
Needham reiterates Buy on Absci and raises price target to $11
EQUITY | Jun 24, 2026, 08:01 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Wednesday's intraday session, with Pulsenmore and Icecure Medical leading the gainers and Aditxt and Atlantic International among the losers
EQUITY | Jun 24, 2026, 05:05 PM UTC
H
KB Home Beats Q2 Sales
KB Home reports Q2 revenue of $1.11 billion, beating analyst estimates, and earnings of 43 cents per share, missing estimates
EARNINGS | Jun 24, 2026, 02:00 PM UTC
H
ABSI Raises $100M
Absci Corporation raises $100 million in equity to fund AI-designed hair loss and endometriosis program
EQUITY | Jun 24, 2026, 01:10 PM UTC
H
Small Caps Surge
Several small cap stocks are experiencing significant gains premarket due to various positive news announcements, including strategic partnerships and favorable trial data.
EQUITY | Jun 24, 2026, 12:21 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Wednesday's pre-market session, with Pulsenmore and Catheter Precision leading the gainers and Nuwellis and Mobile-health Network leading the losers
EQUITY | Jun 24, 2026, 12:09 PM UTC
M
ABSI Prices $100M Offering
Absci prices underwritten offering of 13,495,277 shares at $7.41 per share
EQUITY | Jun 24, 2026, 10:42 AM UTC
M
ABSI: Reports Interim Phase 1 Data
Absci reports interim phase 1 data from its trial of ABS-201, an investigational anti-prolactin receptor antibody, showing favorable safety data.
EARNINGS | Jun 24, 2026, 10:37 AM UTC
H
ABSI Reports Positive Phase 1 Data
Absci announces positive interim phase 1 data from the HEADLINE trial of ABS-201, a novel antibody targeting the prolactin receptor
EQUITY | Jun 24, 2026, 10:30 AM UTC